Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

ClinicalTrials.gov ID: NCT01623596

Public ClinicalTrials.gov record NCT01623596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy. Patients will be be treatment naive or have only been treated with one class of DMT (Interferon beta preparation or glatiramer acetate) . Patients will be able to switch to different treatment for safety, efficacy, tolerability or convenience during the study. Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI.

Study identification

NCT ID
NCT01623596
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
881 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 8, 2012 (Actual)
Primary completion
Jul 13, 2015 (Actual)
Completion
Jul 13, 2015 (Actual)
Last update posted
Jan 5, 2021

2012 – 2015

United States locations

U.S. sites
122
U.S. states
38
U.S. cities
114
Facility City State ZIP Site status
Novartis Investigative Site Cullman Alabama 35058 —
Novartis Investigative Site Phoenix Arizona 85004 —
Novartis Investigative Site Sun City Arizona 85351 —
Novartis Investigative Site Tucson Arizona 85741 —
Novartis Investigative Site Sherwood Arkansas 72120 —
Novartis Investigative Site Fullerton California 92835 —
Novartis Investigative Site Oceanside California 92056 —
Novartis Investigative Site San Francisco California 94117 —
Novartis Investigative Site Walnut Creek California 94598 —
Novartis Investigative Site Basalt Colorado 81621 —
Novartis Investigative Site Boulder Colorado 80301 —
Novartis Investigative Site Denver Colorado 80209 —
Novartis Investigative Site Denver Colorado 80210 —
Novartis Investigative Site Fort Collins Colorado 80528 —
Novartis Investigative Site Fairfield Connecticut 06824 —
Novartis Investigative Site New London Connecticut 06320 —
Novartis Investigative Site Dover Delaware 19901 —
Novartis Investigative Site Atlantis Florida 33462-6608 —
Novartis Investigative Site Bradenton Florida 34205 —
Novartis Investigative Site Delray Beach Florida 33445 —
Novartis Investigative Site Hollywood Florida 33021 —
Novartis Investigative Site Jacksonville Florida 32216 —
Novartis Investigative Site North Palm Beach Florida 33408 —
Novartis Investigative Site Plantation Florida 33324 —
Novartis Investigative Site Pompano Beach Florida 33060 —
Novartis Investigative Site Port Charlotte Florida 33952 —
Novartis Investigative Site Port Orange Florida 32127 —
Novartis Investigative Site Sarasota Florida 34233 —
Novartis Investigative Site Sarasota Florida 34243 —
Novartis Investigative Site St. Petersburg Florida 33713 —
Novartis Investigative Site Tallahassee Florida 32308 —
Novartis Investigative Site Tampa Florida 33609 —
Novartis Investigative Site West Palm Beach Florida 33407 —
Novartis Investigative Site Atlanta Georgia 30312 —
Novartis Investigative Site Columbus Georgia 31904 —
Novartis Investigative Site Decatur Georgia 30083 —
Novartis Investigative Site Suwanee Georgia 30024 —
Novartis Investigative Site Flossmoor Illinois 60422 —
Novartis Investigative Site Northbrook Illinois 60062 —
Novartis Investigative Site Anderson Indiana 46011 —
Novartis Investigative Site Indianapolis Indiana 46227 —
Novartis Investigative Site Indianapolis Indiana 46256 —
Novartis Investigative Site Des Moines Iowa 50314-2611 —
Novartis Investigative Site Overland Park Kansas — —
Novartis Investigative Site Wichita Kansas 67214 —
Novartis Investigative Site Hawesville Kentucky 42384 —
Novartis Investigative Site Lexington Kentucky 40504 —
Novartis Investigative Site Madisonville Kentucky 42431 —
Novartis Investigative Site Alexandria Louisiana 71301 —
Novartis Investigative Site Baton Rouge Louisiana 70809 —
Novartis Investigative Site New Orleans Louisiana 70115 —
Novartis Investigative Site Annapolis Maryland 21401 —
Novartis Investigative Site Fulton Maryland 20759 —
Novartis Investigative Site New Bedford Massachusetts 02740 —
Novartis Investigative Site North Dartmouth Massachusetts 02747 —
Novartis Investigative Site Springfield Massachusetts 01104 —
Novartis Investigative Site Watertown Massachusetts 02472 —
Novartis Investigative Site Worcester Massachusetts 01608 —
Novartis Investigative Site Kalamazoo Michigan 49007 —
Novartis Investigative Site Traverse City Michigan 49684-2340 —
Novartis Investigative Site Nixa Missouri 65714-7807 —
Novartis Investigative Site North Kansas City Missouri 64116 —
Novartis Investigative Site St Louis Missouri 63104 —
Novartis Investigative Site Las Vegas Nevada 89121 —
Novartis Investigative Site Las Vegas Nevada 89123 —
Novartis Investigative Site Las Vegas Nevada 89144 —
Novartis Investigative Site Flemington New Jersey 08822 —
Novartis Investigative Site Teaneck New Jersey 07666 —
Novartis Investigative Site Toms River New Jersey 08755 —
Novartis Investigative Site Albuquerque New Mexico 87108 —
Novartis Investigative Site Albany New York 12208 —
Novartis Investigative Site Amherst New York 14226 —
Novartis Investigative Site Kingston New York 12401 —
Novartis Investigative Site Latham New York 12110 —
Novartis Investigative Site New York New York 10003 —
Novartis Investigative Site Patchogue New York 11772 —
Novartis Investigative Site The Bronx New York 10467-2490 —
Novartis Investigative Site Asheville North Carolina 28806 —
Novartis Investigative Site Charlotte North Carolina 28202 —
Novartis Investigative Site Charlotte North Carolina 28204 —
Novartis Investigative Site Greensboro North Carolina 27401 —
Novartis Investigative Site Greenville North Carolina 27834 —
Novartis Investigative Site Raleigh North Carolina 27607 —
Novartis Investigative Site Salisbury North Carolina 28144 —
Novartis Investigative Site Winston-Salem North Carolina 27103 —
Novartis Investigative Site Grand Forks North Dakota 58201 —
Novartis Investigative Site Akron Ohio 44320 —
Novartis Investigative Site Bellevue Ohio 44811 —
Novartis Investigative Site Canton Ohio 44718 —
Novartis Investigative Site Cincinnati Ohio 45219 —
Novartis Investigative Site Columbus Ohio 43221 —
Novartis Investigative Site Dayton Ohio 45408 —
Novartis Investigative Site Toledo Ohio 43623 —
Novartis Investigative Site Oklahoma City Oklahoma 73104 —
Novartis Investigative Site Oklahoma City Oklahoma 73112 —
Novartis Investigative Site Eugene Oregon 97401 —
Novartis Investigative Site Greensburg Pennsylvania 15601 —
Novartis Investigative Site Hershey Pennsylvania 17033-0850 —
Novartis Investigative Site Pittsburgh Pennsylvania 15212 —
Novartis Investigative Site Cranston Rhode Island 02920 —
Novartis Investigative Site Old Point Station South Carolina 29707 —
Novartis Investigative Site Spartanburg South Carolina 29302 —
Novartis Investigative Site Spartanburg South Carolina 29307 —
Novartis Investigative Site Cordova Tennessee 38018 —
Novartis Investigative Site Knoxville Tennessee 37920 —
Novartis Investigative Site Nashville Tennessee 37205 —
Novartis Investigative Site Colleyville Texas 76034 —
Novartis Investigative Site Houston Texas 77074 —
Novartis Investigative Site Lubbock Texas 79410 —
Novartis Investigative Site North Richland Hills Texas 76180 —
Novartis Investigative Site Plano Texas 75075 —
Novartis Investigative Site Round Rock Texas 78681 —
Novartis Investigative Site San Antonio Texas 78229 —
Novartis Investigative Site Orem Utah 84058 —
Novartis Investigative Site Alexandria Virginia 22310 —
Novartis Investigative Site Norfolk Virginia 23507 —
Novartis Investigative Site Vienna Virginia 22182 —
Novartis Investigative Site Bothell Washington 98011 —
Novartis Investigative Site Seattle Washington 98101 —
Novartis Investigative Site Tacoma Washington 98405 —
Novartis Investigative Site Morgantown West Virginia 26506-9260 —
Novartis Investigative Site Neenah Wisconsin 54956 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01623596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 5, 2021 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01623596 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →